Yvan Le Huerou

USPTO Granted Patents = 12 (Patent Applications = 1)

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 8.2

ph-index = 6

Forward Citations = 75(Granted Patents)

Company Filing History:

Eli Lilly and Company

where one patent can have more than one assignee

Years Active: 2007-2018

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9969727 - Pyrrolopyridines as kinase inhibitors (2018-05-15),

2. 9365568 - Pyrrolopyridines as kinase inhibitors (2016-06-14),

3. 8981085 - Pyrrolopyridines as kinase inhibitors (2015-03-17),

4. 8889704 - Triazolopyridine compounds as PIM kinase inhibitors (2014-11-18),

5. 8865726 - Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors (2014-10-21),

6. 8841304 - Pyrrolopyridines as kinase inhibitors (2014-09-23),

7. 8758830 - Pyrrolopyridines as kinase inhibitors (2014-06-24),

8. 8545897 - Pyrrolopyridines as kinase inhibitors (2013-10-01),

9. 8372842 - Pyrazolopyridines as kinase inhibitors (2013-02-12),

10. 8178131 - Pyrrolopyridines as kinase inhibitors (2012-05-15),

11. 7879885 - Thioalkeneamides as transketolase inhibitors (2011-02-01),

12. 7214673 - Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders (2007-05-08),

Title: Yvan Le Huerou: Innovator in Kinase Inhibition

Introduction

Yvan Le Huerou is a prominent inventor based in Boulder, CO (US). He has made significant contributions to the field of biochemistry, particularly in the development of kinase inhibitors. With a total of 12 patents, his work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Yvan has developed pyrrolopyridines as kinase inhibitors. These compounds are useful for the inhibition of CHK1 and/or CHK2. The methods disclosed involve the use of these compounds and their stereoisomers, as well as pharmaceutically acceptable salts, for in vitro, in situ, and in vivo diagnosis, prevention, or treatment of disorders in mammalian cells, along with associated pathological conditions.

Career Highlights

Yvan has worked with notable companies in the pharmaceutical industry, including Array Biopharma Inc. and Eli Lilly and Company. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Some of his coworkers include Eli M Wallace and James F Blake. Their collaborative efforts have contributed to advancements in the field of kinase inhibitors.

Conclusion

Yvan Le Huerou's innovative work in the development of kinase inhibitors showcases his dedication to advancing medical science. His contributions are likely to have a lasting impact on the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.